Contact
searchSearch
HMP Global
Login

HRR

Videos

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer
12/12/2023
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of...
12/12/2023
Oncology
Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre
Videos
Prevalence of DNA Repair Defects Among Patients With Metastatic Prostate Cancer
11/02/2023
Shahneen Sandhu, MBBS
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational...
11/02/2023
Oncology
Elena Castro, MD, PhD Hospital Universitario 12 de Octubre
Videos
Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations
11/01/2023
Elena Castro, MD, PhD
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final...
11/01/2023
Oncology
Eleni Efstathiou, MD, Houston Methodist Cancer Center
Videos
Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations
02/27/2023
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary...
02/27/2023
Oncology
Paul Swiecicki, MD
Videos
Subcutaneous Amivantamab Triplet Achieves High Response Rates in Recurrent or Metastatic Head and Neck Cancer
11/05/2026
Paul Swiecicki, MD, discusses results from cohort 5 of the OrigAMI-4 trial evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma, highlighting...
Paul Swiecicki, MD, discusses results from cohort 5 of the OrigAMI-4 trial evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma, highlighting...
Paul Swiecicki, MD, discusses...
11/05/2026
Oncology
Andrea Necchi, MD
Videos
ENERGIZE Trial Demonstrates No EFS Benefit With Perioperative Nivolumab Plus Chemotherapy in Muscle-Invasive Bladder Cancer
11/05/2026
Andrea Necchi, MD
Andrea Necchi, MD, discusses final results from the phase 3 ENERGIZE trial evaluating perioperative nivolumab plus gemcitabine and cisplatin in muscle-invasive bladder cancer, highlighting the absence of significant event-free survival or...
Andrea Necchi, MD, discusses final results from the phase 3 ENERGIZE trial evaluating perioperative nivolumab plus gemcitabine and cisplatin in muscle-invasive bladder cancer, highlighting the absence of significant event-free survival or...
Andrea Necchi, MD, discusses...
11/05/2026
Oncology
Kohei Shitara, MD
Videos
Arcotatug Tavatecan Significantly Improves PFS in CLDN18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
11/05/2026
Kohei Shitara, MD
Kohei Shitara, MD, discusses results from the phase 3 G-HOPE-001 trial evaluating arcotatug tavatecan versus chemotherapy in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, highlighting significant...
Kohei Shitara, MD, discusses results from the phase 3 G-HOPE-001 trial evaluating arcotatug tavatecan versus chemotherapy in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, highlighting significant...
Kohei Shitara, MD, discusses...
11/05/2026
Oncology
Kohei Shitara, MD
Videos
Updated HERIZON-GEA-01 Results Demonstrate Overall Survival Benefit With Zanidatamab-Based Regimens in HER2-Positive Gastroesophageal Cancer
11/05/2026
Kohei Shitara, MD
Kohei Shitara, MD, discusses updated results from the phase 3 HERIZON-GEA-01 trial evaluating zanidatamab plus chemotherapy, with or without tislelizumab, in HER2-positive gastroesophageal cancer, highlighting improved overall survival with...
Kohei Shitara, MD, discusses updated results from the phase 3 HERIZON-GEA-01 trial evaluating zanidatamab plus chemotherapy, with or without tislelizumab, in HER2-positive gastroesophageal cancer, highlighting improved overall survival with...
Kohei Shitara, MD, discusses...
11/05/2026
Oncology
Ajai Chari, MD
Videos
Bispecific and Trispecific Antibodies Advance Earlier Treatment of Relapsed or Refractory Multiple Myeloma
11/04/2026
Ajai Chari, MD
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses...
11/04/2026
Oncology
Mateo Mejia Saldarriaga, MD
Videos
AQUILA Findings Fuel Debate Over Treatment Intensification in High-Risk Smoldering Myeloma
11/04/2026
Mateo Mejia Saldarriaga, MD
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD,...
11/04/2026
Oncology
Vivek Subbiah, MD
Videos
Tumor-Agnostic Therapies Advance Precision Oncology Through Comprehensive Biomarker Testing
11/04/2026
Vivek Subbiah, MD
Vivek Subbiah, MD, discusses advances in tumor-agnostic precision oncology, highlighting comprehensive genomic profiling, actionable molecular alterations, and biomarker-directed therapies across cancer types, as well as the importance of...
Vivek Subbiah, MD, discusses advances in tumor-agnostic precision oncology, highlighting comprehensive genomic profiling, actionable molecular alterations, and biomarker-directed therapies across cancer types, as well as the importance of...
Vivek Subbiah, MD, discusses...
11/04/2026
Oncology
Joseph Mikhael, MD
Videos
Optimizing Treatment Intensity and Dosing in Older and Frail Patients With Multiple Myeloma
11/03/2026
Joseph Mikhael, MD, MEd, FRCPC
Joseph Mikhael, MD, discusses individualized treatment strategies for older and frail patients with multiple myeloma, highlighting comprehensive frailty assessment, dose optimization of lenalidomide, bortezomib, and dexamethasone, and...
Joseph Mikhael, MD, discusses individualized treatment strategies for older and frail patients with multiple myeloma, highlighting comprehensive frailty assessment, dose optimization of lenalidomide, bortezomib, and dexamethasone, and...
Joseph Mikhael, MD, discusses...
11/03/2026
Oncology
Daniel King, MD, PhD
Videos
Guiding Treatment Selection and Response Assessment in Metastatic Pancreatic Cancer
11/03/2026
Daniel King, MD, PhD
Daniel King, MD, PhD, reviews the clinical decision-making behind the management of a patient with suspected metastatic pancreatic cancer, highlighting the role of molecular profiling in guiding treatment selection and clinical trial...
Daniel King, MD, PhD, reviews the clinical decision-making behind the management of a patient with suspected metastatic pancreatic cancer, highlighting the role of molecular profiling in guiding treatment selection and clinical trial...
Daniel King, MD, PhD, reviews...
11/03/2026
Oncology
Efrat Dotan, MD; Mary Larse, MSN, RN, OCN; Meredith Pelster, MD, MSCI
Videos
Clinical Perspectives: A Case-Based Discussion of Targeted Therapy in Metastatic Pancreatic Cancer
11/02/2026
Efrat Dotan, MD; Mary Larsen, MSN, RN, OCN; Meredith Pelster, MD
In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the...
In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the...
In this case-based discussion,...
11/02/2026
Oncology

News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
Allison Casey
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

Quizzes

Quiz
Nirogacestat in Young Adult Patients With Desmoid Tumors
10/08/2026
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of...
10/08/2026
Oncology
Quiz
Progression-Free Survival Outcomes With Pegylated Liposomal Doxorubicin in Patients With Desmoid Tumors
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
Quiz
Tiragolumab Plus Atezolizumab and Chemotherapy in ES-SCLC
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
Safety and Preliminary Activity of Eganelisib in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
Polycythemia Vera Management Pre-Survey
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Quiz
Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 4
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 3
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 2
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
OLN

HRR

ALIASES

Human recombination repair

References

Homologous recombination repair (HHR) is a DNA repair mechanism that removes damaged DNA by acting on double-strand breaks, interstrand crosslinks, and other kinds of DNA damage.1 DNA damage is repaired with high fidelity by correcting damage with information copied from a homologous undamaged molecule.2 Defects in HRR are present in some cancers.3

Recent News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
Allison Casey
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use